J Gastroenterol Hepatol Endosc | Volume 3, Issue 3 | Short Communication | Open Access
Zahide Simsek1, Müyesser Sayki2, Seyda Sahingoz3, Serpil Erdoğan4 and Akif Altınbas1,5*
1Department of Gastroenterology, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Gastroenterology Clinic, Turkey
2Department of Endocrinology, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Endocrinology Clinic, Turkey
3Department of Biochemistry, Dıskapı Yıldırım Beyazıt Education and Research Hospital, Biochemistry Clinic, Turkey
4Department of Biochemistry, Ataturk Education and Research Hospital, Biochemistry Clinic, Turkey
5Department of Gastroenterology, Massachusetts General Hospital, Gastrointestinal Unit, USA
*Correspondance to: Akif Altınbas
Fulltext PDFBackground and
Aim: Intragastric Balloon (IGB) placement is an effective way for weight loss. However, the impact of IGB on some biomarkers is still unknown. We investigated the impact of IGB placement on these markers.
Methods: Thirty individuals undergoing IGB and 40 lean controls were enrolled. M30, M65, adiponectin and thiol- disulfide levels were measured at baseline and at the six months of IGB placement.
Results: At baseline, patients had significantly higher ALT, M30 and M65 levels compared to the controls. M30, M65, adiponectin, thiol- disuphide levels and MPV were all found to be similar at the beginning and end of the IGB therapy.
Conclusion: Our results revealed that IGB placement did not enhance the biomarkers of interest in the six months of follow up.
Morbid Obesity; M30 level; M65 level; Adiponectin values; Thiol level; Disulphide level
Simsek Z, Sayki M, Sahingoz S, Erdoğan S, Altınbas A. M30 and M65 levels as well as MPV, Adiponectin and Thiol-Disulphide Values are not Improving during Intragastric Balloon Placement Therapy in Morbid Obese Patients: A Single Center, Case Control Study. J Gastroenterol Hepatol Endosc. 2018;3(3):1047.